Precigen, Inc. (PGEN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Precigen, Inc. (PGEN) Healthcare & Pipeline Overview

Precigen, Inc. is a biotechnology firm specializing in gene and cell therapy development, leveraging platforms like UltraVector and AdenoVerse to create innovative therapeutics and biotechnology solutions. With a focus on disease modification and regenerative medicine, Precigen operates in a competitive landscape of advanced biotechnology companies.

What Is the Investment Thesis for PGEN?

Precigen, Inc. presents a high-risk, high-reward investment thesis centered on its innovative gene and cell therapy platforms. Key value drivers include the successful development and commercialization of its UltraCAR-T and AdenoVerse Immunotherapy platforms. The company's diverse technology portfolio offers multiple avenues for growth, but its negative profit margin of -2588.2% highlights the significant financial challenges. Upcoming catalysts include clinical trial results for its lead candidates and potential partnerships. Investors should monitor the company's cash burn rate and ability to secure additional funding. The company's beta of 1.12 suggests higher volatility compared to the overall market.

Based on FMP financials and quantitative analysis

PGEN Key Highlights

Market capitalization of $2.38B reflects investor expectations for future growth in the gene and cell therapy market.

• Gross margin of 42.1% indicates potential for profitability as products move through clinical trials and towards commercialization.
• The company's focus on innovative platforms like UltraVector and AdenoVerse positions it at the forefront of gene and cell therapy development.
• Collaboration agreements with multiple companies demonstrate the potential for partnerships and revenue generation.
• Change of name from Intrexon Corporation to Precigen, Inc. in January 2020 signifies a strategic shift towards a more focused approach on gene and cell therapies.

Who Are PGEN's Competitors?

PGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PGEN's Key Strengths?

Innovative technology platforms (UltraVector, AdenoVerse).

• Diverse portfolio of therapeutic programs.
• Strategic collaborations with leading companies.
• Expertise in gene and cell therapy development.

What Are PGEN's Weaknesses?

High operating expenses and negative profit margin.

• Dependence on clinical trial outcomes.
• Limited commercialized products.
• Potential regulatory hurdles.

What Could Drive PGEN Stock Higher?

Clinical trial results for UltraCAR-T platform in hematological malignancies.

• Data readout from AdenoVerse immunotherapy studies in solid tumors.
• Potential partnerships for commercialization of ActoBiotics platform.
• Advancements in regenerative medicine applications using genetically engineered swine.
• Expansion of intellectual property portfolio through new patent filings.

What Are the Key Risks for PGEN?

Financial-distress signal — its Altman Z-Score of -9.29 sits in the distress zone (elevated bankruptcy risk).

• Insider selling — insiders were net sellers of roughly $11.9M recently.
• Unfavorable clinical trial results for key therapeutic programs.
• Regulatory delays or rejections for new products.
• Competition from established pharmaceutical companies.
• High operating expenses and cash burn rate.
• Patent disputes and intellectual property challenges.

What Are the Growth Opportunities for PGEN?

• UltraCAR-T Platform Expansion: Precigen's UltraCAR-T platform represents a significant growth opportunity in the oncology market. The global CAR-T cell therapy market is projected to reach $5.29 billion by 2029, growing at a CAGR of 21.7% from 2022. By expanding the application of its UltraCAR-T platform to treat a broader range of cancers, Precigen can capture a larger share of this expanding market. This involves ongoing clinical trials and potential partnerships with other pharmaceutical companies to accelerate development and commercialization.
• AdenoVerse Immunotherapy Development: The AdenoVerse Immunotherapy platform offers a growth avenue through the development of novel immunotherapies. The global immunotherapy market is expected to reach $414.4 billion by 2030, growing at a CAGR of 13.3% from 2021. Precigen can leverage its AdenoVerse platform to create targeted immunotherapies for various diseases, including cancer and infectious diseases. Success hinges on positive clinical trial results and strategic collaborations to expand the platform's reach.
• Regenerative Medicine Applications: Precigen's genetically engineered swine for regenerative medicine applications presents a unique growth opportunity. The regenerative medicine market is projected to reach $121.6 billion by 2030, growing at a CAGR of 21.8% from 2021. By developing and commercializing genetically engineered tissues and organs for transplantation, Precigen can address the critical shortage of donor organs and improve patient outcomes. This requires overcoming regulatory hurdles and establishing partnerships with transplant centers.
• ActoBiotics Platform Commercialization: The ActoBiotics platform, which delivers proteins and peptides at mucosal sites, offers a growth opportunity in the treatment of gastrointestinal and other mucosal diseases. The global market for microbiome therapeutics is expected to reach $1.79 billion by 2028, growing at a CAGR of 22.1% from 2021. Precigen can leverage its ActoBiotics platform to develop targeted therapies for conditions like inflammatory bowel disease and infectious diarrhea. This involves conducting clinical trials and securing regulatory approvals for its ActoBiotics-based products.
• Strategic Partnerships and Licensing Agreements: Precigen can drive growth through strategic partnerships and licensing agreements with other biotechnology and pharmaceutical companies. By collaborating with partners to develop and commercialize its technologies, Precigen can expand its reach and access new markets. This includes licensing its UltraVector, AdenoVerse, and ActoBiotics platforms to other companies for use in their own research and development programs. Successful partnerships can provide significant revenue streams and accelerate the development of Precigen's technologies.

What Are PGEN's Competitive Advantages?

• Proprietary Technology Platforms: Precigen's UltraVector, AdenoVerse, and ActoBiotics platforms provide a competitive advantage through unique capabilities in gene and cell therapy development.
• Intellectual Property Portfolio: The company's extensive patent portfolio protects its innovative technologies and provides a barrier to entry for competitors.
• Strategic Collaborations: Partnerships with leading pharmaceutical and biotechnology companies enhance Precigen's reach and accelerate the development of its products.
• Expertise in Genetic Engineering: Precigen's team of scientists and engineers possesses deep expertise in genetic engineering and synthetic biology, enabling the company to develop novel therapeutic solutions.

What Does PGEN Do?

Precigen, Inc., founded in 1998 and formerly known as Intrexon Corporation until its rebranding in January 2020, is a biotechnology company headquartered in Germantown, Maryland. The company is dedicated to discovering and developing next-generation gene and cellular therapies. Precigen's portfolio includes disease-modifying therapeutics, genetically engineered swine for regenerative medicine applications, and reproductive and embryo transfer technologies. Its core offerings are built around several key technology platforms. The UltraVector platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs. Other platforms include mbIL15, Sleeping Beauty, AttSite recombinases, and AdenoVerse. These technologies are applied in the development of innovative therapies and solutions across various healthcare applications. Precigen also offers RheoSwitch, an inducible gene switch system, kill switches for cell therapies, tissue-specific promoters, UltraCAR-T platform for cancer treatment, AdenoVerse Immunotherapy, and ActoBiotics platform. The company collaborates with entities like Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., Intrexon Energy Partners, LLC, and Intrexon Energy Partners II, LLC, to expand its research and development efforts and commercial reach.

What Products and Services Does PGEN Offer?

• Discovers and develops gene and cellular therapies.
• Provides disease-modifying therapeutics.
• Develops genetically engineered swine for regenerative medicine.
• Offers reproductive and embryo transfer technologies.
• Provides the UltraVector platform for advanced DNA construction.
• Develops the AdenoVerse technology platform for gene delivery.
• Offers the RheoSwitch inducible gene switch system.
• Develops the UltraCAR-T platform for cancer treatment.

How Does PGEN Make Money?

• Develops and licenses gene and cell therapy technologies.
• Generates revenue through collaboration and license agreements.
• Conducts research and development to create innovative therapeutics.
• Commercializes its therapeutic products through partnerships or direct sales.

What Industry Does PGEN Operate In?

Precigen operates within the rapidly evolving biotechnology industry, specifically in the gene and cell therapy sector. This market is characterized by high growth potential, driven by advancements in genetic engineering and increasing demand for personalized medicine. The competitive landscape includes companies like TERN: Terns Pharmaceuticals, Inc. and DNTH: Dianthus Therapeutics, Inc., as well as larger pharmaceutical firms investing in gene and cell therapies. The industry is subject to stringent regulatory requirements and high research and development costs. Market trends include the development of novel delivery systems and the expansion of gene and cell therapies into new therapeutic areas.

Who Are PGEN's Key Customers?

• Pharmaceutical companies seeking gene and cell therapy technologies.
• Research institutions conducting studies in regenerative medicine.
• Hospitals and clinics offering advanced cancer treatments.
• Patients in need of innovative therapeutic solutions.

Over the past six months, Precigen, Inc. insiders filed 90 SEC Form 4 transactions — 53 sales and 37 purchases. On net that is roughly 1.9M shares disposed (about $11.9M), a signal worth weighing alongside the fundamentals.

Precigen, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 96.9% below estimates on average.

Precigen, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -9.29 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.1%, the inverse of the P/E and a quick read on earnings relative to price.

Precigen, Inc. (PGEN) Valuation Context

Valued at $2.38B, PGEN is classified as a mid-cap stock. Analyst price targets span from $18.00 to $18.00, with a consensus of $18.00. At the current price of $6.68, that implies approximately 169% upside potential. Relative to its peer group, PGEN's quantitative score of 10/100 is below the peer average of 81/100.

PGEN Revenue & Earnings Trend

In Q2 FY2026, PGEN generated $55.0M in top-line revenue, marking a sequential increase of 136.4%. The company recorded net income of $20.1M, with diluted EPS of $0.05. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, PGEN averaged $-0.14 in diluted EPS.

Company Profile

Precigen, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Germantown, US. The company is led by CEO Helen Sabzevari. PGEN has traded publicly since 2013.

PGEN Financials

PGEN Latest News

PGEN Analyst Consensus

PGEN MoonshotScore

PGEN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources